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Abstract
Background—Cardiac myosin heavy chain-α (Myhc), an intracellular protein expressed in the 
cardiomyocytes, has been identified as a major autoantigen in cardiac autoimmunity. In our 
studies with Myhc334-352-induced experimental autoimmune myocarditis in A/J mice (H-2a), we 
discovered that Myhc334-352, supposedly a CD4 T cell epitope, also induced antigen-specific CD8 
T cells that transfer disease to naïve animals.
Methods and Results—In our efforts to identify the CD8 T cell determinants, we localized 
Myhc338-348 within the full length-Myhc334-352, leading to four key findings. (1) By acting as a 
dual epitope, Myhc338-348 induces both CD4 and CD8 T cell responses. (2) In a major 
histocompatibility complex (MHC) class I-stabilization assay, Myhc338-348 was found to bind 
H-2Dd – but not H-2Kk or H-2Ld – alleles. (3) The CD8 T cell response induced by Myhc338-348 
was antigen-specific, as evaluated by MHC class I/H-2Dd dextramer staining. The antigen-
sensitized T cells predominantly produced interferon-γ, the critical cytokine of effector cytotoxic 
T lymphocytes. (4) Myhc338-348 was found to induce myocarditis in immunized animals as 
determined by histology and magnetic resonance microscopy imaging.
Conclusions—Our data provide new insights as to how different immune cells can recognize 
the same antigen and inflict damage through different mechanisms.
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1. Introduction
Autoimmunity ensues when immune responses are directed against self-antigens, resulting 
from the mediation of either autoantibodies or autoreactive T cells. However, when 
autoreactive T cells are involved, CD4 T helper (Th) cells are commonly implicated because 
they play a central role in the generation of adaptive immune responses. For example, 
cytokines produced by CD4 T cells are critical for B cells to produce antibodies to protein 
antigens, and Th cytokines like interferon (IFN)-γ mediate macrophage activation. On the 
other hand, interleukin (IL)-2 helps in the differentiation and expansion of CD8 T cells. 
Because CD4 T cells are needed for B cells to make antibodies, both cell types are expected 
to recognize the same antigens, but their epitopes could be different. Thus, an argument can 
be made that therapeutically targeting the pathogenic autoreactive B cells that produce 
autoantibodies, as well as the CD4 T cells that help the B cells do so, can suppress 
autoimmune responses in diseases driven by antibodies, such as systemic lupus 
erythematosus, Hashimoto's thyroiditis, Sjogren's syndrome, and rheumatoid arthritis [1, 2].
CD4 T cells and CD8 T cells are distinct in their recognition of peptides, in that they 
recognize antigens presented by two different molecules of the major histocompatibility 
complex (MHC) locus. While MHC class II molecules expressed by professional antigen-
presenting cells (APCs) present peptides to CD4 T cells, MHC class I molecules expressed 
by almost all nucleated cells can present peptides to CD8 T cells. The ends of peptide-
binding grooves are open in the class II MHC molecules, enabling them to present long 
peptides (up to 20 amino acids), as opposed to short peptides of ~8-11 amino acids 
presented by class I molecules, in which the ends of the MHC-clefts are closed [3, 4]. 
Therefore, the immunodominant epitopes of protein antigens can be processed and presented 
in the context of class I or class II molecules through endogenous and exogenous pathways, 
respectively, leading to the induction of corresponding CD8 and CD4 T cell responses. If 
such an event happens for self-proteins, then the tissue destruction in the target organs is 
mediated by CD4 T cells via delayed-type hypersensitivity reaction, whereas CD8 T cells 
inflict damage through cytolysis [2, 5].
To study the immune events of cardiac autoimmunity, rodent models of experimental 
autoimmune myocarditis (EAM) are commonly employed. These include cardiac myosin 
heavy chain-α (Myhc)334-352-induced EAM in A/J (H-2a), CBA/J (H-2k) and B10.A (H-2k) 
mice; Myhc614-643-induced EAM in Balb/c (H-2d) mice; and Myhc1304-1320-induced EAM 
in Lewis rats (RT1) [6-11]. The disease is induced by immunizing the animals with the 
immunodominant epitopes of cardiac antigens in complete Freund’s adjuvant (CFA). In all 
the EAM models described above, the disease has been shown to be mediated by CD4 T 
cells, [8, 10, 11] with a complex disease pathogenesis [12-14]. In our studies with EAM 
induced by Myhc334-352 in A/J mice, however, we noted an unexpected finding that the full-
length Myhc334-352 (FL-Myhc334-352) epitope was also found to contain Myhc338-348, which 
is a determinant for CD8 T cells. By acting as a dual epitope, Myhc338-348 induces both CD4 
and CD8 T cell responses that are antigen-specific, and induces myocarditis in immunized 
animals through the predominant production of IFN-γ, the critical cytokine of effector 
cytotoxic lymphocytes.
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2. Materials and Methods
2.1 Mice
Our studies involved the use of 6- to 8-week-old female A/J mice (H-2a), obtained from the 
Jackson Laboratory (Bar Harbor, ME) and maintained in accordance with the guidelines of 
the University of Nebraska-Lincoln. All animals used in the study received humane care, 
and the Institutional Animal Care and Use Committee approved experimental permit and 
protocol numbers are A3459-01 and 973, respectively.
2.2 Peptide synthesis and immunization procedures
The indicated peptides, including the controls (bovine ribonuclease [RNase]43-56, 
VNTFVHESLADVQA; human immunodeficiency virus glycoprotein 120 [HIV]P18-I10, 
RGPGRAFVTI), were synthesized on 9-fluorenylmethyloxycarbonyl chemistry 
(Neopeptide, Cambridge, MA). All peptides were HPLC-purified (>90%), identity-
confirmed by mass spectroscopy, and dissolved in 1x PBS prior to use. For immunizations, 
peptides were emulsified in CFA supplemented with Mycobacterium tuberculosis H37RA 
extract to a final concentration of 5 mg/ml, and administered subcutaneously in multiple 
sites in the flank and sternal regions (100 μg per mouse). For EAM induction, animals were 
immunized twice as above at 7 day intervals, and pertussis toxin (100 ng/mouse) was 
administered on day 0 and day 2 after the first immunization [11, 15].
2.3 Measurement of recall responses and derivation of primary T cell cultures
Fourteen days after immunization, animals were euthanized and single cell suspensions were 
prepared using the draining lymph nodes (maxillary, mandibular, axillary, inguinal and 
popliteal) and spleens [11, 15]. After lysing the erythrocytes with 1x ammonium chloride 
potassium buffer (Lonza, Walkersville, MD) and washing, cells were resuspended in 1x 
IMAG buffer (BD Biosciences, San Diego, CA). CD4 or CD8 T cells were then enriched to 
a purity of >95 % by negative selection based on magnetic separation using IMAG (BD 
Biosciences) [15]. Cells were suspended in growth medium containing RPMI medium 
supplemented with 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, 4 mM L-
glutamine, 1x each of non-essential amino acids and vitamin mixture, and 100 U/ml 
penicillin-streptomycin (Lonza). To measure the recall responses, cells were stimulated for 2 
days at a density of 10 × 106 cells/ml in the presence of syngeneic irradiated APCs at a ratio 
of 1:1, as well as the indicated peptides (0-100 μg/ml). After pulsing with 1 μCi of 
tritiated 3[H]-thymidine (MP Biomedicals, Santa Ana, CA) for 16 hours, proliferative 
responses were measured as counts per minute (cpm) using a Wallac liquid scintillation 
counter (Perkin Elmer, Waltham, MA) [11]. To derive primary T cell cultures, whole cell 
populations were stimulated with the peptides (50 μg/ml), and supplemented after two days 
with IL-2 medium (eBioscience, San Diego, CA; Advanced Biotechnologies, Columbia, 
MD) [11, 15].
2.4 Disease induction by adoptive transfer
A/J mice were immunized with FL-Myhc334-352 in CFA, and at termination on day 14, 
spleens and lymph nodes were harvested to prepare single cell suspensions. CD8 T cells 
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were then enriched by negative selection based on magnetic separation as described in 
section 2.3, then stimulated with concanavalin-A (Con-A, 2.5 μg/ml; Sigma Aldrich, St. 
Louis, MO) for two days. Viable cells were harvested and administered i.p., (14 × 106 cells 
per animal) into whole body-irradiated (400 rads/mouse) naïve animals [16-19]. Irradiated 
naïve mice that received 1 × PBS or Con-A activated CD8 T cells obtained from naïve mice, 
served as controls. Additionally, each mouse received pertussis toxin (100 ng/mouse) i.p., on 
day 0 and day 2 posttransfer, and the animals were euthanized on day 18 to harvest hearts 
for histology.
2.5 Staining for markers of effector CD8 T cells
Groups of A/J mice were immunized with Myhc334-352, and after 10 days, lymph nodes 
were obtained and lymph node cells (LNCs) were prepared. Cells were stimulated with the 
peptide (50 μg/ml) for 2 days, and the cultures were maintained in IL-2 medium. On days 4, 
6, 8 and 10 post-stimulation, cells were stained with CD8 and CD107a/b or Rat-IgG2a 
(isotype control) antibodies (eBioscience), and 7-amino-actinomycin-D (7-AAD; Invitrogen, 
Carlsbad, CA). After washing, cells were acquired by flow cytometry (FACS Calibur, BD 
Biosciences, San Diego, CA), and the frequencies of CD107a/b+ cells were enumerated in 
the live (7-AAD−) CD8 T cell subset using Flow Jo software (Tree Star, Ashland, OR) [20, 
21]. Similarly, on the indicated days, after staining with CD8 antibodies and 7-AAD, cells 
were fixed and permeabilized, then stained with granzyme B or perforin antibodies and Rat-
IgG2a (isotype control) [22-24]. After washing, cells were acquired by flow cytometry and 
the frequencies of granzyme B+ and perforin+ cells were enumerated in the live (7-AAD−) 
population as above.
2.6 MHC class I stabilization assay
To identify the epitopes that bind MHC molecules, we used a MHC class I stabilization 
assay [25], which involved the use of a transporter associated with antigen-processing 2-
deficient RMA-S cell lines that were stably transfected with these MHC class I genes: 
H-2Dd (kind gift from David H. Raulet, University of California, Berkeley), H-2Kk (kind 
gift from Peter Cresswell, Yale School of Medicine, New Haven), and H-2Ld (kind gift from 
Ted Hansen, Washington University, St. Louis). RMA-S-Dd cells were cultured in Kappler-
Marrack complete tumor medium [26]. RMA-S-Kk and RMA-S-Ld cells were cultured in 
RPMI medium supplemented with 10% FBS, 10 mM HEPES, 2 mM L-glutamine and 100 
U/ml penicillin-streptomycin. Briefly, cells were plated in 96-well plates at a density of 2 × 
106/ml and were incubated with or without Trunk A-4 and Trunk A-5 peptides (0 to 400 
μM) at 26°C/5% CO2 for 18 hours. The plates were then transferred to a 37°C incubator for 
1.5 hours, and after washing, cells were stained with fluorophore-labelled antibodies for 
H-2Dd (BD Pharmingen, San Diego, CA), H-2Kk (BD Pharmingen), and H-2Ld (Cedarlane, 
Burlington, NC). After washing, cells were acquired by flow cytometry, and the mean 
fluorescence intensities (MFI) were calculated using CellQuest software (BD Biosciences). 
Finally, MFI ratios were derived using the formula: MFI ratio = (MFI observed in the 
presence of peptide at 37°C/MFI observed in the absence of peptide at 26°C) – (MFI 
observed in the absence of peptide at 37°C/MFI observed in the absence of peptide at 26°C) 
× 100 [25].
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2.7 Derivation of MHC dextramers and determination of antigen-specificity of Myhc-
reactive T cells by dextramer staining
The antigen specificity of Myhc-reactive CD4 T cells was determined by MHC class II/IAk 
dextramer staining. MHC class II/IAk dextramers (Myhc334-352 and RNase43-56), were 
prepared as we have described previously [27]. CD4 T cells obtained from mice immunized 
with Myhc334-352 were stimulated with the peptide (50 μg/ml) for 2 days, and the cells were 
maintained in IL-2 medium. On day 8, cells were stained with dextramers for two hours at 
room temperature followed by staining with anti-CD4 and 7-AAD [27]. After washing, cells 
were acquired by flow cytometry, and the percentages of dextramer+ cells were determined 
in the live (7-AAD−) cell populations using Flow Jo software.
The antigen specificity of Myhc-reactive CD8 T cells was determined by MHC class I/
H-2Dd dextramer staining. The process followed three stages.
2.7.1 Expression of MHC class I heavy chains and β2-microglobulin (β2m)—
Derivation of MHC class I dextramers required the expression of the class I heavy chain for 
H-2Dd and the light chain β2m. The expression vector for the mouse MHC class I heavy 
chain of H-2Dd was constructed as previously described [28]. Briefly, the full-length 
extracellular domains of the H-2Dd allele were amplified from the cDNA synthesized from 
the splenocytes of naïve A/J mice using the sequence-specific forward and reverse primers 
5'GGGAATTCATATGGGCTCACACTCGCTGAGG3' and 5'AGAGGATCCGGATGAAG 
GAGGCTCCTCCTTGCC3'. The forward and reverse primers were designed to include the 
in-frame Nde1 site/start codon and in-frame BamH1 sites, respectively. The amplified 
fragments were digested with the respective enzymes and cloned into a pET22b+ vector 
(Novagen, Madison, WI). Finally, the sequence for the biotinylation site 
(5’GATCCCTGCATCATATTC 
TGGATGCACAGAAAATGGTGTGGAATCATCGTTAAA3’) was cloned immediately 
after the codon for the 280th amino acid of the MHC class I heavy chain [28].
The construct for human β2m (pHN1-β2m) was received as a kind gift from Dr. David 
Garboczi [29]. MHC class I monomers and β2m were expressed in BL21(DE3)pLysS 
competent cells (Promega, Madison, WI) induced by isopropyl β-D-1-thiogalactopyranoside 
(ThermoScientific, Waltham, MA) at a final concentration of 1 mM and 0.4 mM, 
respectively [28]. The proteins expressed as insoluble inclusion bodies were purified, 
solubilized in urea and stored snap-frozen in aliquots at −80°C until use [28].
2.7.2 Preparation of H-2Dd dextramers—The heavy chain of H-2Dd was refolded with 
β2m and Trunk A-4, Trunk A-5 or Trunk A-6 peptides in individual reactions as described 
previously [28]. To prepare control dextramers, we used HIVP18-I10, which binds the H-2Dd 
allele, as reported by others [30]. Briefly, peptides (1.5 mg), β2m (2000 nM), and MHC 
heavy chain (1000 nM) dissolved in injection buffer (3 mM guanidine HCl, 10 mM sodium 
acetate, 10 mM EDTA, pH 4.2) were injected sequentially into a beaker containing folding 
buffer (100 mM Tris base, 0.4 M L-arginine, 2 mM EDTA, pH 8.0, supplemented with 5 
mM reduced glutathione, 0.5 mM oxidized glutathione and 100 mM phenylmethylsulfonyl 
fluoride) at 4°C with continuous stirring. At 12 hours and 18 hours post incubation, the 
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reaction mixtures were supplemented with additional amounts of heavy chain protein (1000 
nM), and the incubation was continued for a total of 36 hours. The precipitate containing 
unfolded protein complexes was removed by centrifuging the samples at 13,000 rpm for 20 
minutes, and the MHC heavy chain/β2m/peptide complexes in the supernatant were 
concentrated using ultracentrifugal filters (Millipore, Billerica, MA). These complexes were 
then desalted using gel-filtration columns (GE Healthcare Bio-Sciences, Pittsburgh, PA) and 
biotinylated using the biotin ligase, BirA ([25 μg or 10 nM; Avidity, Denver, CO]/ 2.5 
mg/ml of the MHC/peptide complexes) at 30°C overnight. After desalting, biotinylated 
MHC/peptide monomers were assembled with dextran-streptavidin-phycoerythrin molecules 
(kindly provided by Immudex Aps, Copenhagen, Denmark) at a molar ratio of 20:1 by 
incubating the reaction mixtures at room temperature (RT) for 30 minutes in the dark, 
followed by reconstitution in the dextramer buffer (50 mM Tris Hcl, pH 7.2). The reagents 
were stored at 4°C until use.
2.7.3 Dextramer staining—To ascertain the antigen specificity of the CD8 T cells, we 
used H-2Dd dextramers, which included specific (H-2Dd/Trunk A-4, H-2Dd/Trunk A-5 and 
H-2Dd/Trunk A-6) and control (H-2Dd/ HIVP18-I10) dextramers [27]. Briefly, LNCs 
obtained from the animals immunized with FL-Myhc334-352 were stimulated with the 
immunizing peptide (50 μg/ml), and on day 5 post stimulation, viable cells were harvested 
and maintained in IL-2 medium. Cells harvested on day 8 were washed and chilled on ice 
for 20 minutes, followed by staining with the MHC class I dextramers using FBS (2.5%)-
supplemented IL-2 medium, pH 7.63, at RT for 1 hour. Cells were washed and stained with 
anti-CD8, anti-CD4 and 7-AAD. After washing, cells were acquired by flow cytometry, and 
the percentages of dextramer+ CD8+ cells were determined in the live (7-AAD−) population 
using Flow Jo software.
2.8 Intracellular cytokine staining
Single cell suspensions were prepared from mice immunized with FL-Myhc334-352, Trunk 
A-4 peptide or Trunk A-5 peptide on day 14 post immunization. Cells (5x106/ml) were 
stimulated with the immunizing peptides (50 μg/ml) for two days, and IL-2 medium was 
then added. On day 6, viable cells were stimulated briefly with phorbol-12-myristate 13-
acetate (PMA; 20 ng/ml) and ionomycin (300 ng/ml; Sigma Aldrich) in the presence of 
monensin (2 mM; Golgi stop; BD Pharmingen) for 5 hours. Cells were washed and stained 
with antibodies for CD4 and CD8 (eBioscience) and 7-AAD. After washing and fixing, cells 
were permeabilized and stained with cytokine antibodies or their respective isotype controls 
(rat IgG1, rat IgG2a and rat IgG2b). Cells were acquired by flow cytometry, and frequencies 
of cytokine-producing CD4 or CD8 T cells were analyzed in the live (7-AAD−) population 
using Flow Jo software by utilizing the gates drawn for isotype controls corresponding to 
each cytokine [11]. The following clones of cytokine antibodies were used: IL-2 
(JES6-5H4); IFN-γ (XMG1.2); IL-4 (11B11); IL-10 (JES5-16E3); IL-17A (eBio 17B7); 
IL-17 F (eBio 18F10); and tumor necrosis factor (TNF)-α (MP6-XT22) (all from 
eBioscience) and IL-22 (140301; R&D Systems, Minneapolis, MN).
Massilamany et al. Page 6
Int J Cardiol. Author manuscript; available in PMC 2017 January 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
2.9. Histopathology
Hearts were collected at termination on day 21 post immunization with the peptides, and the 
tissues were fixed by immersion in 10% phosphate buffered formalin [11, 31]. Three 
longitudinal sections 5 μm thick were made from each heart and stained with hematoxylin 
and eosin (H and E). The sections were examined by a board-certified pathologist blinded to 
treatment. Inflammation and severity scores were obtained based on the total number of 
inflammatory foci added across the three sections, deriving the percent inflammation as 
reported previously [9].
2.10 Magnetic resonance microscopy (MRM imaging)
To determine the structural and functional abnormalities of hearts in mice affected with 
myocarditis, we used MRM imaging as a non-invasive tool [32]. Briefly, mice were 
anaesthetized using 2% isoflurane; a rectal thermometer was placed in the rectum to monitor 
body temperature, and a pulse oximeter was connected to monitor the heart rate. An animal 
monitoring system involving respirometry and pulse oximetry was used to minimize image 
blurring due to respiratory and cardiac movements. Animals were subjected to MRM 
imaging using a wide-bore (89 mm) 9.4 T vertical-bore magnet (Varian, Inc. Walnut Creek, 
CA) equipped with triple axis gradients of 100 G/cm and a 4 cm radio-frequency imaging 
coil as described previously [32]. Using an echo-based cine pulse sequence, short-axis slices 
of hearts were captured in eight time frames and stored. The images were analyzed using 
Segment software (Segment v1.8 R1430, Medviso, Sweden) to determine the changes, if 
any, in the structural (left ventricular [LV] wall thickness) and functional parameters (end 
diastolic volume and ejection fraction).
2.11 Statistics
Student's t-test was used to determine differences in T cell proliferative responses, MHC 
class I stabilization assay, cytokine-producing cells, and degree of inflammation between 
groups. p ≤ 0.05 values were considered significant.
3. Results
3.1 A/J mice immunized with FL-Myhc334-352 show generation of antigen-specific CD4 and 
CD8 T cell responses
EAM induced with FL-Myhc334-352 has been used to study the cellular mechanisms of 
cardiac autoimmunity that involve the mediation of Myhc-reactive CD4 T cells [6, 11]. 
However, by characterizing the infiltrates of the hearts, we noted that CD8 T cells 
contributed a proportion of T cells (CD3+ CD8+: 3.50 ± 1.40%; CD3+ CD4+:11.84 ± 
5.09%), leading us to conduct tests to determine their antigen specificity. Groups of A/J 
mice were immunized with Myhc334-352, and after 14 days, CD4 and CD8 T cells were 
enriched by negative selection with a purity of more than 95% (Fig. 1, top panel). Cells were 
stimulated with irradiated APCs pulsed with Myhc334-352 to measure the proliferative 
responses based on 3[H]-thymidine-incorporation assay. Predictably, CD4 T cells 
specifically and significantly responded to Myhc334-352 (p<0.0053), since the responses to a 
control peptide, RNase43-56, were absent (Fig. 1, bottom left panel). Their antigen specificity 
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was later confirmed by staining the cells with MHC class II/IAk dextramers. In brief, LNCs 
from mice immunized with Myhc334-352 were stimulated with the peptide and the cells were 
rested in IL-2 medium. Viable cells harvested on day 8 were stained with IAk/Myhc334-352 
and RNase43-56 (control) dextramers, leading to the detection of Myhc-specific CD4 T cells 
(2.59±0.32%) since the staining for control dextramers was negligible (0.24±0.073%) 
(Supplemental fig. 1; p=0.00016). However, unexpectedly, CD8 T cells obtained from 
immunized animals also responded to Myhc334-352, dose- and antigen-dependently, and the 
responses were significant when compared with control (p<0.00058; Fig. 1, bottom right 
panel). Importantly, the magnitude of CD8 T cell responses was comparable to that of CD4 
T cells, as the responses between the two did not differ significantly.
We then asked if the CD8 T cells were to respond to Myhc, whether the antigen-sensitized 
cells would produce IFN-γ, the signature cytokine of CD8 T cells. To test this possibility, 
LNCs from immunized mice were stimulated with Myhc334-352, and their cytokine-
producing abilities were tested in relation to CD4 and CD8 T cell subsets. Supplemental 
figure 2 shows that the cells capable of producing Th1 (IFN-γ) and Th17 (IL-17A, IL-17F 
and IL-22) cytokines were predominant, followed by IL-10-producing Th2 cells. In contrast, 
under the same conditions, the IFN-γ-producing ability of CD8 T cells was enhanced four-
fold (p≤0.0032), but Th17 cytokines were limited to IL-17F and IL-22, and IL-10-producing 
cells were negligible. The enhanced IFN-γ-producing ability of CD8 T cells further 
supported our proposal that they might be antigen-specific and play a role in disease 
mediation.
To determine the pathogenic role of Myhc-reactive CD8 T cells, lymphocytes were obtained 
from animals immunized with Myhc334-352, and the CD8 T cells were enriched. After 
stimulating with Con-A for two days, cells were administered into naïve animals. Upon 
evaluating hearts at termination on day 18, we detected inflammatory foci accompanied by 
hemorrhagic necrosis and mineralization in the recipients of antigen-primed CD8 T cells 
(Fig. 2ai and 2aii), but not in the saline group (Fig. 2aiii) or the recipients of naïve CD8 T 
cells (Fig. 2aiv). This finding suggested that Myhc-reactive CD8 T cells are pathogenic, and 
the effector mechanisms might involve their cytolytic functions. Consistent with this notion, 
we verified that Myhc334-352-reactive CD8 T cells express granzyme B (Fig. 2b left panel; 
p<0.027) and perforin (Fig. 2b middle panel; p<0.026) intracellularly, and express CD107a/
CD107b (Fig. 2b right panel; p<0.020), the surface markers of degranulation process of 
effector cells [20-22, 24, 33, 34].
3.2 Localization of CD8 T cell epitopes within the FL-Myhc334-352
CD8 T cells generally recognize epitopes with a length of 8 to 11 amino acids, although they 
can recognize longer peptides [3, 35-37]. However, in our case, the finding that the 19-mer 
FL-Myhc334-352 induced CD8 T cell responses suggested that the CD8 T cell epitopes must 
be localized within this peptide sequence, and identification of these determinants required 
three levels of screening.
In the primary screening, we sought to use the truncated peptides Trunk A (Myhc334-349), 
Trunk B (Myhc338-352), Trunk C (Myhc334-347) and Trunk D (Myhc340-352), generated from 
FL-Myhc334-352 in a proliferation assay, in which the truncations resulted from the deletions 
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of 3 to 6 amino acids from the N- or C-terminal ends in each (Table 1). Briefly, CD4 and 
CD8 T cells were enriched from animals immunized with Myhc334-352, as above, and the 
cells were tested for their responses to Myhc334-352 (positive control), truncated peptides and 
RNase43-56 (negative control), leading us to make two observations.
(a) D4 T cells responded vigorously to Myhc334-352 (p=0.03) as well as Trunk A (p=0.02) 
and Trunk B (p=0.02) peptides, but their responses to Trunk C and Trunk D peptides were 
progressively reduced (Fig. 3, top panels). The responses to Myhc peptides were specific, 
since the antigen-sensitized T cells did not respond to the control. These patterns were 
expected because the putative MHC class II (IAk)-binding residue Asp at position 338 
(Asp338), as well as the two CD4 T cell receptor (TCR)-contact residues (Ala348, major; and 
Ala344, minor), for CD4 T cells are preserved in both Trunk A and Trunk B (Table 1, [6]). 
As such, the relative reduction in response to Trunk C was expected because the major 
TCR-contact residue Ala348 is lacking (Table 1). Although the Trunk D peptide contains 
both TCR-contact residues, the response was low, perhaps because the peptide lacked the 
putative MHC-binding residue, Asp338.
(b) Like CD4 T cells, CD8 T cells also responded to various truncated peptides of Myhc, but 
not the control, with similar trends in a decreasing order (Trunk A > Trunk B > Trunk C > 
Trunk D; Fig. 3, bottom panels). The magnitude of responses to Trunk A and Trunk B 
peptides, was significantly higher than responses to the control (RNase 43-56, p<0.05). 
Since, the Trunk A peptide (with deletions of three amino acids [VYK] at the C-terminus) 
showed a comparable response to that obtained with the Trunk B peptide (with deletions of 
four amino acids [DSAF] at the N-terminus) (Table 1), we focused on the central core 
region (12-mer: DVLSFTAEEKAG), which was common to both in order to identify shorter 
peptides that could potentially induce CD8 T cell responses. In support of this proposal, we 
noted that responses to the Trunk C peptide, with deletion of two additional residues (AG) at 
the C-terminus, and to the Trunk D peptide, with deletion of six residues (DSAFDV) at the 
N-terminus, remained low (Fig. 3, bottom panels).
In the secondary screening, within the Trunk A peptide we designed six 10-mer to 12-mer 
peptides labelled Trunk A-1 to Trunk A-6 (Table 2). We enriched CD4 and CD8 T cells 
from mice immunized with FL-Myhc334-352 and evaluated their responses to these six 
peptides.
As shown in figure 4 (top panels), Trunk A-4 and Trunk A-5 peptides induced the responses 
in CD8 T cells (p≤0.009), and if any, the responses for Trunk A-4 were better than FL-
Myhc334-352 (p=0.02), whereas responses for Trunk A-6 were absent. Likewise, responses to 
three other peptides (Trunk A-1, A-2 and A-3) also were marginal (data not shown).
Furthermore, our attempts to reduce the length of Trunk A-4, and A-5 peptides to fewer than 
10 amino acids did not yield better results. To this end, we designed 9-mer peptides, based 
on the epitope prediction database [38]. Proliferative responses, as indicated by stimulation 
indices, were marginal compared with responses obtained with the control peptide 
(RNase43-56) (Supplemental table 1).
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In contrast to CD8 T cells however, while all three peptides (Trunk A-4, A-5 and A-6) 
induced responses in the CD4 T cells comparable to responses induced by Myhc334-352, 
responses to Trunk A-4 and Trunk A-5 (p≤0.005), but not Trunk A-6 (p=0.061), were 
significantly higher than responses to the control (Fig. 4, bottom panels). We had expected 
the responses to Trunk A-5 (with a deletion of major TCR-contact residue Ala348) and 
Trunk A-6 (with a deletion of putative MHC-contact residue Asp338) to be lower than 
responses to Trunk A-4, which contained both the MHC-contact residue Asp338 and two 
TCR-contact residues (Ala344; and Ala348; Table 1). But that was not the case.
We thus identified Trunk A-4 and Trunk A-5 as the putative Myhc peptides that induce both 
CD4 and CD8 T cell responses. The immunogenicity of these peptides was later confirmed 
by immunizing groups of mice. As expected, CD4 T cells responded comparably to both 
Trunk A-4 and A-5 peptides, whereas the response to Trunk A-6 was weak (Supplemental 
fig. 3, top panels). In contrast, CD8 T cells responded to a greater degree to Trunk A-4 
followed by Trunk A-5, and the least response was obtained for Trunk A-6 peptides 
(Supplemental fig. 3, bottom panels).
3.3 Identification of MHC class I allele that binds CD8 T cell epitopes
It has been previously shown that the FL-Myhc334-352 binds the IAk (MHC class II) allele in 
A/J mice. Since this mouse strain expresses three MHC class I alleles – H-2Dd, H-2Kk and 
H-2Ld – it was necessary to determine the specific allele that presents the Myhc peptides to 
CD8 T cells. This was examined via an MHC class I stabilization assay that involved the use 
of RMA-S cell lines expressing H-2Dd, H-2Kk and H-2Ld alleles, which stabilize MHC 
molecules on their surface when the MHC-expressing cells bind with peptides [39]. We used 
fluorophore-conjugated allele-specific antibodies to ascertain MHC stability, determining 
the difference in the MFI ratios between cells loaded with or without peptides by flow 
cytometry. By using the peptides that induced the CD8 T cell responses (Trunk A-4 and 
Trunk A-5), we found that the MFI ratios obtained with RMA-S-Dd cells were significantly 
higher for Trunk A-5 peptides (p≤0.03) compared to cells incubated with no peptide (Fig. 5). 
Although MFI ratios obtained for Trunk A-4 were lower than those obtained with Trunk A-5 
peptides, the ratios were significantly higher than those obtained with the control peptide, 
especially at a concentration of 200 μM or more (p≤0.05). Under similar conditions, 
however, neither of the two peptides bound to RMA-S-Kk- and RMA-S-Ld-expressing cells 
(data not shown). Thus, we identified Trunk A-4 and Trunk A-5 peptides as the binders of 
the H-2Dd molecule. These results were further corroborated using T2-Dd cells (kind gift 
from Ted Hansen, Washington University, St. Louis; and Joyce Solheim, University of 
Nebraska Medical Center, Omaha), which also showed stronger affinity for Trunk A-5 than 
Trunk A-4 (data not shown).
3.4 Antigen-specificity of CD8 T cells sensitized with FL-Myhc334-352
After identifying Trunk A-4 and Trunk A-5 peptides as the putative CD8 T cell epitopes 
based on peptide screening and MHC-stabilization assay, we sought to create MHC class I 
dextramers and we recently showed that the MHC dextramers were found to be superior to 
tetramers in various experimental settings [27, 40, 41]. We generated H-2Dd dextramers by 
conjugating the peptide-loaded, biotinylated H-2Dd protein assembled with the β2m as 
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described previously [27]. Essentially, we prepared dextramers for Trunk A-4, Trunk A-5 
and Trunk A-6 peptides (control) and used them to determine the specificity of CD8 T cells 
generated in response to Myhc334-352. The expectation was that H-2Dd dextramers of Trunk 
A-4 and A-5, but not A-6, peptides would bind CD8 T cells, but none would bind CD4 T 
cells. Briefly, LNC cultures were prepared from A/J mice immunized with Myhc334-352, and 
the cells were stained with the dextramers and CD4 and CD8 antibodies. As shown in figure 
6, H-2Dd/Trunk A-4 (2.74±0.34%; p≤0.0014) and H-2Dd/Trunk A-5 (1.79±0.29%; 
p≤0.0042) dextramers stained the Myhc334-352-sensitized CD8 T cells, whereas the staining 
for control (Trunk A-6 dextramers) was negligible (0.05±0.008%). Similarly, dextramers 
prepared using the irrelevant control antigen HIVP18-I10 also did not stain the cells 
(0.04±0.0058%), indicating that the staining obtained with H-2Dd /Trunk A-4 and A-5 
dextramers was specific. Additionally, none of the H-2Dd dextramers stained the CD4 T 
cells generated in mice immunized with Myhc334-352, further ensuring the specificity of the 
MHC class I dextramers (Fig. 6). Taken together, the patterns of staining obtained with 
H-2Dd dextramers and the MHC-stabilization assay were identical, indicating that the two 
CD8 T cell epitopes (Trunk A-4 and Trunk A-5) are localized within Myhc334-352.
3.5 Determination of the pathogenic potential of Myhc-sensitized CD8 T cells
To determine the pathogenic potential of antigen-sensitized CD8 T cells, we analyzed their 
cytokine-producing abilities and compared the responses with CD4 T cells [11]. In brief, 
LNCs from mice immunized with Myhc334-352 were restimulated with the Trunk peptides 
(A-4, and A-5) and Myhc334-352, and the frequencies of cytokine-producing cells were 
evaluated for Th1, Th2 and Th17 cytokines and TNF-α. As shown in figure 7 (left panels), 
cells capable of producing Th1 (IFN-γ) cytokines and TNF-α were predominantly present in 
both CD4 and CD8 T cell cultures, followed by Th17 and Th2 cytokines. Importantly, when 
the cytokine profiles of CD4 and CD8 T cell subsets were compared, it was evident that the 
frequencies of IFN-γ-secreting cells were consistently greater in the CD8 T cell cultures, 
regardless of peptides used (Myhc334-352: 11.19 ± 1.08 vs 1.98 ± 0.43, p = 0.02E-02; Trunk 
A-4: 12.87 ± 0.46 vs 2.85 ± 0.54, p = 8.08E-06; Trunk A-5: 14.40 ± 1.62 vs 2.96 ± 0.48, p = 
4.91E-05). Conversely, percentages of cells producing Th2 cytokines tended to be greater in 
CD4 T cells stimulated with Trunk A-4 and A-5 peptides (Fig. 7, right panels). No other 
major differences were noted for other cytokines except that CD8 T cell cultures produced 
fewer IL-17F-producing cells than did CD4 T cells (p≤0.009). The findings that the cytokine 
patterns obtained in CD8 T cell cultures with the Trunk peptides A-4 and A-5 were 
comparable to those produced with Myhc334-352, and that their responses were largely 
similar to those produced in CD4 T cells suggest that the A-4 and A-5 peptides might be 
able to induce disease.
3.6 Evaluation of disease induced with Trunk A-4 and Trunk A-5 peptides
We evaluated the disease-inducing abilities of peptides by immunizing groups of mice with 
Trunk A-4 and Trunk A-5 and compared the disease severity, as assessed by histology, with 
that of Myhc334-352, which was used as a positive control (Fig. 8). While all three peptides 
induced myocarditis showing infiltrations of mononuclear cells, the disease severity induced 
with Trunk A-4 and A-5 peptides was lower than that induced by Myhc334-352 (Fig. 8; 
Myhc334-352: incidence, 5/5; percent area inflamed, 12.8 ± 5.54). However, among the two 
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truncated peptides, the disease incidence (Trunk A-4, 6/13; Trunk A-5, 3/9) and the 
homogeneity of histological changes (percent area inflamed: Trunk A-4, 3 ± 0.75; Trunk 
A-5, 10.7 ± 7.22) were more consistent with Trunk A-4 than Trunk A-5. We also made 
efforts to determine whether the disease induced with the truncated peptides could also be 
captured non-invasively. To provide a proof-of-principle for this analysis, we subjected the 
animals immunized with Trunk A-4 peptides to MRM imaging to evaluate structural and 
functional abnormalities. The data revealed that the LV wall thickness in the Trunk A-4-
immunized mice was increased by ~1.35-fold (p≤2.25E-05) in relation to age-matched 
healthy mice (Supplemental fig. 4a). Likewise, measurement of cardiac output parameters 
indicated that both end diastolic volumes (p≤3.45E-05) and ejection fractions (p≤5.67E-07) 
were low in the myocarditic mice compared to healthy controls (Supplemental fig. 4b). 
Taken together, the data suggest that the Trunk A-4 and Trunk A-5 peptides can induce 
myocarditis, and the histological features are similar to those of myocarditis induced by 
Myhc334-352.
4. Discussion
We report here the localization of the CD8 T cell determinant, Myhc338-348 that induces 
EAM in A/J mice. Previously, it has been shown that Myhc334-352, an immunodominant 
epitope that binds the MHC class II allele IAk, induces myocarditis in IAk-expressing A/J 
mice through the generation of Myhc-reactive CD4 T cells [6, 10, 11, 15]. We recently 
created MHC class II/IAk tetramers and dextramers and demonstrated that Myhc334-352-
specific CD4 T cells are generated in the peripheral repertoire and infiltrate the hearts of 
immunized animals [15, 27]. However, by examining the heart infiltrates, we noted that 
CD8 T cells also formed a component of the T cell fraction (~35% of T cells), leading us to 
determine their potential role in the mediation of cardiac autoimmunity.
We first verified that the responses of CD8 T cells from the animals immunized with 
Myhc334-352 were comparable with responses of CD4 T cells (Fig. 1). Importantly, we 
confirmed that Myhc-sensitized CD8 T cells produce IFN-γ (Supplemental fig. 2) and 
express markers CD107a/CD107b, granzyme and perforin, the markers of their effector 
functions, and transfer disease to naïve animals (Fig. 2). Based on these observations, we 
decided to localize the CD8 T cell epitopes within FL-Myhc334-352 
(DSAFDVLSFTAEEKAGVYK). In this peptide, three amino acid residues were previously 
identified to be critical (Asp338, MHC class II/IAk-anchor; and Ala344-minor; and Ala348-
major TCR-contacts; Table 1), where deletion of major TCR contact residue Ala348 was 
found to reduce CD4 T cell responses [6]. Hence, during the primary screening, we took an 
approach to ablate the CD4 T cell responses by designing peptides to retain or to delete the 
MHC (Asp338)- or the major TCR (Ala348)-contact residues. These include trunk A and 
trunk B (both contain MHC- and TCR-contact residues); trunk C (lacks the TCR-contact 
residue); and trunk D (lacks the MHC-contact residue) (Table 1). Predictably, we noted the 
responses for Trunk A and Trunk B in CD4 T cells, whereas the responses for Trunk C and 
Trunk D were low (Fig. 3). In contrast, the two truncated peptides (Trunk A and Trunk B), 
containing all three residues essential for the induction of CD4 T cell responses, also 
induced comparable responses in CD8 T cells (Fig. 3). These data pointed to a possibility 
that the central core region (DVLSFTAEEKAG) may encompass the CD8 T cell epitope/s, 
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with the further possibility that CD4 T cell responses could still be preserved, since the 
MHC class II anchor and the TCR-contact residues for the generation of CD4 T cells were 
still conserved (Table 1).
Reports indicate that the peptides binding to MHC class I molecules can be of variable 
lengths (8 to 11 amino acids), but long peptides up to 15 amino acids can also bind class I 
molecules under the conditions of conformational change of their peptide-binding sites. 
Therefore, we designed a total of six peptides with a length of 10 to 12 amino acids, and 
found that two peptides (Trunk A-4: DVLSFTAEEKA, and Trunk A-5: DVLSFTAEEK) 
induced responses in CD8 T cells comparable to those obtained with FL-Myhc334-352, 
whereas response for Trunk A-6 was absent (Fig. 4). But surprisingly, all three peptides, 
including Trunk A-5, which was missing the major TCR-contact residue Ala348 for CD4 T 
cells, and Trunk A-6, which was missing the class II MHC-anchor residue Asp338 at the N-
terminus, stimulated the CD4 T cells, and their responses were comparable to those 
stimulated by Myhc334-352. These data support the notion that shorter peptides of 10-mers 
can also be presented by MHC class II molecules to CD4 T cells as reported by others 
[42-44]. While our data also suggest the possibility of the existence of an alternative MHC 
class II-anchor residue, the display of major or minor TCR-contact residues in the short 
peptide sequences may still be similar to FL-Myhc334-352. Alternatively, the minor TCR-
contact residue Ala344 may get displayed differently with an altered binding register in the 
absence of the major TCR-contact residue as in Trunk A-5 (Table 2), and such a 
compensatory change may be adequate to facilitate peptide-recognition by TCR. Overall, 
since Trunk A-4 and Trunk A-5 peptides showed comparable responses in CD8 T cells, we 
decided to use these for further experimentation. Finally, after confirming that the MHC 
class I allele H-2Dd presents both Trunk A-4 and Trunk A-5 peptides, we created their 
dextramers and confirmed that the CD8 T cells reacting to Myhc were antigen-specific, 
suggesting they play a role in the development of myocarditis.
To evaluate the pathogenic potential of CD8 T cell epitopes, we first analyzed the cytokine-
producing ability of CD8 T cells based on intracellular staining using panels of Th1, Th2 
and Th17 cytokines and TNF-α. Essentially, the Myhc-reactive CD8 T cell cultures 
contained cells capable of producing all cytokines tested, and their profiles were comparable 
to those of CD4 T cells. Importantly, the frequencies of IFN-γ-producing cells were 
significantly greater in CD8 than in CD4 cultures, except that IL-17F-producing cells were 
low in the cultures responsive to Trunk A-4 and A-5 peptides. However, regardless of cell 
type, Th2 cytokines were consistently low. However, it is to be noted that conflicting reports 
were available as to the role of cytokines in the mediation of autoimmune myocarditis, in 
part, due to the variation in the genetic backgrounds of the mouse strains used [12, 13]. For 
example, IL-13-deficient and IL-12p40-decificient Balb/c mice showed opposing disease 
phenotypes, in that the disease severity was enhanced in IL-13-deficient mice, whereas in 
IL-12p40-deficient mice, the severity was relatively low [13, 45-47]. Conversely, while, 
Balb/c mice deficient for IFN-γ showed more severe disease, the IL-4-deficient A/J mice 
showed an attenuated myocarditis [31, 47]. It is currently held that the cytokines represented 
by both Th1 (IFN-γ) and Th17 (IL-17 family cytokines and IL-22) are critical to the 
mediation of autoimmune myocarditis, since cytokines other than IL-12 produced by APCs, 
such as IL-1, IL-6, IL-23 and transforming growth factor-β, favor the development of 
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proinflammatory Th17 cytokines [13, 46]. However, it is to be noted that IL-17A appears 
not critical for the development of myocarditis as IL-17A-deficient mice can develop severe 
disease [48]. Adding to this complexity is the possibility of plasticity for the interconversion 
of Th1 to Th17 and vice versa [49, 50]. Finally, by verifying the disease-inducing potential, 
we noted that the histological changes observed with myocarditis resulting from Trunk A-4 
and Trunk A-5 peptides were comparable to those resulting from FL-Myhc334-352, but the 
disease severity induced by the Trunk peptides remained mild to moderate (Fig. 8). The 
relative lower ability of CD8 T cells to produce IL-17F (Fig. 7), which otherwise contributes 
to the aggravation of inflammation by promoting neutrophil/monocyte migration [51, 52], 
might explain the lower disease severity induced with the determinants for CD8 T cells.
4.1 Limitations
In this study, we noted the following limitations: (i) for intracellular cytokine staining, we 
could not compare the cytokine profiles obtained with Myhc peptide-stimulations, with the 
cells cultured in medium-alone, or the cells stimulated with the irrelevant peptide, since the 
cells in the latter two conditions were not expected to be viable in the cultures for six days. 
Although, we evaluated the cytokine-secretion based on cytokine bead array analysis in the 
whole cell cultures specific to Myhc peptides (data not shown), we could not analyze the 
cytokines in the individual CD4 and CD8 subsets enriched by magnetic separation; (ii) we 
performed the MHC class I stabilization assay based on published protocols, but these 
protocols do not involve the use of a positive control peptide; its use otherwise would have 
been helpful to compare the affinity of Myhc peptides; (iii) the animals immunized with 
Trunk A-5 peptide were not subjected for MRM imaging since the incidence of disease 
induced with this peptide was low; and (iv) we made no efforts to identify the amino acid 
residues within Myhc338-348 that are critical for binding MHC class I (H-2Dd) and the TCR 
of CD8 T cells.
5. Conclusion
We have demonstrated that Myhc338-348 acts as a dual epitope for both CD4 and CD8 T 
cells, and the CD8 T cell epitopes induce myocarditis through the generation of Myhc-
specific IFN-γ-producing cells. Interestingly, the shorter peptides, Trunk A-5 and A-6, 
lacking the major TCR-contact residue and MHC class II-anchor, respectively, also induced 
CD4 T cell responses comparable to those produced by FL-Myhc334-352. These observations 
may lead to the conclusion that a proportion of antigen-specific CD4 T cells that arise in 
response to Myhc334-352 may be the result of recognition of shorter peptides possibly 
generated by the processing of FL-Myhc334-352 by APCs. In this scenario, the presence of 
the single TCR-contact residue Ala344 in FL-Myhc334-352, supposedly a minor TCR-contact 
residue in Trunk A-5, may be sufficient to induce activation of CD4 T cells. During this 
process, the cardiac-reactive CD8 T cells can also be produced and participate in the disease 
pathogenesis. Thus, the hierarchical generation of cardiac-reactive CD4 and CD8 T cells 
may be possible, but they may collectively contribute to the tissue destruction. Although the 
disease induced by CD4 cells is typically mediated by Th1 and Th17 cytokines, in addition 
to their cytolytic functions, cytokines produced by CD8 T cells similar to Th1 and Th17 
phenotypes [53, 54] also have been implicated. Furthermore, Myhc, being an intracellular 
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protein, is expressed by cardiac myocytes, and the resident APCs in A/J mice have also been 
shown to display fragments of Myhc [6]. Yet, the animals do not develop myocarditis 
spontaneously, possibly because of self-tolerance due to the lack of costimulatory signals. In 
inflammatory conditions, however, upregulation of costimulatory molecules may favor the 
presentation of peptides, leading to a break in self-tolerance, and cardiac autoimmunity may 
ensue, possibly involving the generation of Myhc-reactive CD4 and CD8 T cells. Of note, 
the generation of pathogenic, dual T cell-specific responses through the recognition of a 
single epitope similar to Myhc334-352 has been described for at least three other self-
antigens, myelin oligodendrocyte glycoprotein 35-55, cancer testes antigen and 
interphotoreceptor retinoid-binding protein 201-216 [42, 55-57]. However, reports also 
indicate that induction of antigen-specific CD8 T cells can be potentially beneficial to 
controlling autoimmune responses, because CD8 T cells that lack the expression of CD28 
can behave as regulatory T (Treg) cells, as shown in systemic lupus erythematosus and 
rheumatoid arthritis [58-60]. This was not the case, however, with Myhc-specific CD8 T cell 
responses, because the Myhc-reactive cells were positive for CD28, and did not express 
other markers of Treg cells like forkhead box P3 (data not shown). Nonetheless, the finding 
that a solitary peptide fragment bearing the epitopes for two different T cell types induced 
myocarditis provides new insights as to how different immune cells can recognize the same 
antigen and mediate cardiac damage by different mechanisms. In autoimmune settings, 
identification of the disease-inducing epitopes and their cellular mechanisms may possibly 
create opportunities to target antigen-specific T cells for therapy. As to human relevance, 
IgG autoantibodies for various cardiac antigens like cardiac myosin, β1-adrenergic receptor, 
cardiac troponin I, Na-K-ATPase and heart-specific mitochondrial inner membrane proteins 
M7 type A and cardiac adenine-nucleotide transporter have been demonstrated in patients 
with myocarditis/dilated cardiomyopathy, and experimentally, in animal models of adjuvant 
and viral myocarditis, but their pathological significance continues to be uncertain [61-65]. 
However, the requirement that T cell help is critical for B cells to produce IgG antibodies 
suggests that cardiac-reactive T cells might play a pathogenic role. Our data may point to 
this possibility.
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Myhc cardiac myosin heavy chain-α
MHC major histocompatibility complex
Th T helper
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IL interleukin
APCs antigen-presenting cells
EAM experimental autoimmune myocarditis
CFA complete Freund’s adjuvant
FL-Myhc full-length Myhc
RNase bovine ribonuclease
HIV human immunodeficiency virus envelope glycoprotein
3[H]-thymidine tritiated-thymidine
cpm counts per minute
Con-A concanavalin-A
LNCs lymph node cells
7-AAD 7-amino-actinomycin-D
MFI mean fluorescence intensities
β2m β2microglobulin
PMA phorbol-12-myristate 13-acetate
Bir A biotin ligase
RT room temperature
TNF tumor necrosis factor
H and E hematoxylin and eosin
MRM magnetic resonance microscopy
LV left ventricular
TCR T cell receptor
Treg regulatory T cells
References
[1]. Hampe CS. B Cell in Autoimmune Diseases. Scientifica. 2012:2012.
[2]. Ken Murphy, PT.; Mark, Walport. Immunobiology: The Immune System in Health and Disease. 
Taylor & Francis; New York: 2007. 
[3]. Guo HC, Jardetzky TS, Garrett TP, Lane WS, Strominger JL, Wiley DC. Different length peptides 
bind to HLA-Aw68 similarly at their ends but bulge out in the middle. Nature. 1992; 360:364–6. 
[PubMed: 1448153] 
[4]. O'Brien C, Flower DR, Feighery C. Peptide length significantly influences in vitro affinity for 
MHC class II molecules. Immunome Res. 2008; 4:6. [PubMed: 19036163] 
[5]. Abbas, AK.; Lichtman, AH.; Pillai, S. Cellular and molecular immunology. 6th. Saunders 
Elsevier; Philadelphia: 2010. 
Massilamany et al. Page 16
Int J Cardiol. Author manuscript; available in PMC 2017 January 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
[6]. Donermeyer DL, Beisel KW, Allen PM, Smith SC. Myocarditis-inducing epitope of myosin binds 
constitutively and stably to I-Ak on antigen-presenting cells in the heart. J Exp Med. 1995; 
182:1291–300. [PubMed: 7595200] 
[7]. Kodama M, Matsumoto Y, Fujiwara M, Masani F, Izumi T, Shibata A. A novel experimental 
model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. 
Clin Immunol Immunopathol. 1990; 57:250–62. [PubMed: 2208806] 
[8]. Neu N, Rose NR, Beisel KW, Herskowitz A, Gurri-Glass G, Craig SW. Cardiac myosin induces 
myocarditis in genetically predisposed mice. J Immunol. 1987; 139:3630–6. [PubMed: 3680946] 
[9]. Pummerer CL, Luze K, Grassl G, Bachmaier K, Offner F, Burrell SK, et al. Identification of 
cardiac myosin peptides capable of inducing autoimmune myocarditis in BALB/c mice. J Clin 
Invest. 1996; 97:2057–62. [PubMed: 8621795] 
[10]. Smith SC, Allen PM. Myosin-induced acute myocarditis is a T cell-mediated disease. J Immunol. 
1991; 147:2141–7. [PubMed: 1918949] 
[11]. Massilamany C, Gangaplara A, Steffen D, Reddy J. Identification of novel mimicry epitopes for 
cardiac myosin heavy chain-alpha that induce autoimmune myocarditis in A/J mice. Cell 
Immunol. 2011; 271:438–49. [PubMed: 21939961] 
[12]. Christoph Berger UE. Autoimmune Murine Myocarditis and Immunomodulatory Interventions. 
Inflammatory Cardiomyopathy (DCMi) – Pathogenesis and Therapy: Birkhäuser Basel. 2010:37–
49.
[13]. Cihakova D, Rose NR. Pathogenesis of myocarditis and dilated cardiomyopathy. Adv Immunol. 
2008; 99:95–114. [PubMed: 19117533] 
[14]. Penninger JM, Pummerer C, Liu P, Neu N, Bachmaier K. Cellular and molecular mechanisms of 
murine autoimmune myocarditis. APMIS. 1997; 105:1–13. [PubMed: 9063494] 
[15]. Massilamany C, Gangaplara A, Chapman N, Rose N, Reddy J. Detection of cardiac myosin 
heavy chain-alpha-specific CD4 cells by using MHC class II/IA(k) tetramers in A/J mice. J 
Immunol Methods. 2011; 372:107–18. [PubMed: 21782819] 
[16]. Gangaplara A, Massilamany C, Brown DM, Delhon G, Pattnaik AK, Chapman N, et al. 
Coxsackievirus B3 infection leads to the generation of cardiac myosin heavy chain-alpha-
reactive CD4 T cells in A/J mice. Clin Immunol. 2012; 144:237–49. [PubMed: 22854287] 
[17]. Barin JG, Talor MV, Baldeviano GC, Kimura M, Rose NR, Cihakova D. Mechanisms of 
IFNgamma regulation of autoimmune myocarditis. Experimental and molecular pathology. 2010; 
89:83–91. [PubMed: 20599938] 
[18]. Elliott JF, Liu J, Yuan ZN, Bautista-Lopez N, Wallbank SL, Suzuki K, et al. Autoimmune 
cardiomyopathy and heart block develop spontaneously in HLA-DQ8 transgenic IAbeta 
knockout NOD mice. Proc Natl Acad Sci U S A. 2003; 100:13447–52. [PubMed: 14570980] 
[19]. Frohlich A, Marsland BJ, Sonderegger I, Kurrer M, Hodge MR, Harris NL, et al. IL-21 receptor 
signaling is integral to the development of Th2 effector responses in vivo. Blood. 2007; 
109:2023–31. [PubMed: 17077330] 
[20]. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, et al. Sensitive and 
viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for 
degranulation. J Immunol Methods. 2003; 281:65–78. [PubMed: 14580882] 
[21]. Kannan K, Stewart RM, Bounds W, Carlsson SR, Fukuda M, Betzing KW, et al. Lysosome-
associated membrane proteins h-LAMP1 (CD107a) and h-LAMP2 (CD107b) are activation-
dependent cell surface glycoproteins in human peripheral blood mononuclear cells which 
mediate cell adhesion to vascular endothelium. Cell Immunol. 1996; 171:10–9. [PubMed: 
8660832] 
[22]. Brown DM, Lee S, Garcia-Hernandez Mde L, Swain SL. Multifunctional CD4 cells expressing 
gamma interferon and perforin mediate protection against lethal influenza virus infection. J Virol. 
2012; 86:6792–803. [PubMed: 22491469] 
[23]. Workman AM, Jacobs AK, Vogel AJ, Condon S, Brown DM. Inflammation enhances IL-2 
driven differentiation of cytolytic CD4 T cells. PLoS One. 2014; 9:e89010. [PubMed: 24586481] 
[24]. Kaiserman D, Bird CH, Sun J, Matthews A, Ung K, Whisstock JC, et al. The major human and 
mouse granzymes are structurally and functionally divergent. The Journal of cell biology. 2006; 
175:619–30. [PubMed: 17116752] 
Massilamany et al. Page 17
Int J Cardiol. Author manuscript; available in PMC 2017 January 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
[25]. Suzuki M, Aoshi T, Nagata T, Koide Y. Identification of murine H2-Dd- and H2-Ab-restricted T-
cell epitopes on a novel protective antigen, MPT51, of Mycobacterium tuberculosis. Infect 
Immun. 2004; 72:3829–37. [PubMed: 15213124] 
[26]. Kappler JW, Skidmore B, White J, Marrack P. Antigen-inducible, H-2-restricted, interleukin-2-
producing T cell hybridomas. Lack of independent antigen and H-2 recognition. J Exp Med. 
1981; 153:1198–214. [PubMed: 6166712] 
[27]. Massilamany C, Upadhyaya B, Gangaplara A, Kuszynski C, Reddy J. Detection of autoreactive 
CD4 T cells using major histocompatibility complex class II dextramers. BMC Immunol. 2011; 
12:40. [PubMed: 21767394] 
[28]. Altman JD, Davis MM. MHC-peptide tetramers to visualize antigen-specific T cells. Curr Protoc 
Immunol. 2003:3. Chapter 17:Unit 17. [PubMed: 18432902] 
[29]. Garboczi DN, Hung DT, Wiley DC. HLA-A2-peptide complexes: refolding and crystallization of 
molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc Natl 
Acad Sci U S A. 1992; 89:3429–33. [PubMed: 1565634] 
[30]. Liu XS, Liu WJ, Zhao KN, Liu YH, Leggatt G, Frazer IH. Route of administration of chimeric 
BPV1 VLP determines the character of the induced immune responses. Immunol Cell Biol. 2002; 
80:21–9. [PubMed: 11869359] 
[31]. Afanasyeva M, Wang Y, Kaya Z, Park S, Zilliox MJ, Schofield BH, et al. Experimental 
autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 
phenotype. Am J Pathol. 2001; 159:193–203. [PubMed: 11438466] 
[32]. Massilamany C, Khalilzad-Sharghi V, Gangaplara A, Steffen D, Othman SF, Reddy J. 
Noninvasive assessment of cardiac abnormalities in experimental autoimmune myocarditis by 
magnetic resonance microscopy imaging in the mouse. Journal of visualized experiments : JoVE. 
2014:e51654. [PubMed: 24998332] 
[33]. Lord SJ, Rajotte RV, Korbutt GS, Bleackley RC. Granzyme B: a natural born killer. Immunol 
Rev. 2003; 193:31–8. [PubMed: 12752668] 
[34]. Packard BZ, Telford WG, Komoriya A, Henkart PA. Granzyme B activity in target cells detects 
attack by cytotoxic lymphocytes. J Immunol. 2007; 179:3812–20. [PubMed: 17785818] 
[35]. Speir JA, Stevens J, Joly E, Butcher GW, Wilson IA. Two different, highly exposed, bulged 
structures for an unusually long peptide bound to rat MHC class I RT1-Aa. Immunity. 2001; 
14:81–92. [PubMed: 11163232] 
[36]. Stevens J, Wiesmuller KH, Walden P, Joly E. Peptide length preferences for rat and mouse MHC 
class I molecules using random peptide libraries. Eur J Immunol. 1998; 28:1272–9. [PubMed: 
9565367] 
[37]. Tynan FE, Borg NA, Miles JJ, Beddoe T, El-Hassen D, Silins SL, et al. High resolution 
structures of highly bulged viral epitopes bound to major histocompatibility complex class I. 
Implications for T-cell receptor engagement and T-cell immunodominance. J Biol Chem. 2005; 
280:23900–9. [PubMed: 15849183] 
[38]. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database 
for MHC ligands and peptide motifs. Immunogenetics. 1999; 50:213–9. [PubMed: 10602881] 
[39]. Correa I, Raulet DH. Binding of diverse peptides to MHC class I molecules inhibits target cell 
lysis by activated natural killer cells. Immunity. 1995; 2:61–71. [PubMed: 7541307] 
[40]. Massilamany C, Gangaplara A, Jia T, Elowsky C, Kang G, Riethoven JJ, et al. Direct staining 
with major histocompatibility complex class II dextramers permits detection of antigen-specific, 
autoreactive CD4 T cells in situ. PLoS One. 2014; 9:e87519. [PubMed: 24475302] 
[41]. Massilamany C, Gangaplara A, Jia T, Elowsky C, Li Q, Zhou Y, et al. In situ detection of 
autoreactive CD4 T cells in brain and heart using major histocompatibility complex class II 
dextramers. Journal of visualized experiments : JoVE. 2014:e51679. [PubMed: 25145797] 
[42]. Shao H, Peng Y, Liao T, Wang M, Song M, Kaplan HJ, et al. A shared epitope of the 
interphotoreceptor retinoid-binding protein recognized by the CD4+ and CD8+ autoreactive T 
cells. J Immunol. 2005; 175:1851–7. [PubMed: 16034128] 
[43]. Buus S, Sette A, Colon SM, Miles C, Grey HM. The relation between major histocompatibility 
complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science. 1987; 
235:1353–8. [PubMed: 2435001] 
Massilamany et al. Page 18
Int J Cardiol. Author manuscript; available in PMC 2017 January 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
[44]. Sercarz EE, Maverakis E. Mhc-guided processing: binding of large antigen fragments. Nat Rev 
Immunol. 2003; 3:621–9. [PubMed: 12974477] 
[45]. Cihakova D, Barin JG, Afanasyeva M, Kimura M, Fairweather D, Berg M, et al. Interleukin-13 
protects against experimental autoimmune myocarditis by regulating macrophage differentiation. 
Am J Pathol. 2008; 172:1195–208. [PubMed: 18403598] 
[46]. Eriksson U. The role of IL-17 in Experimental Autoimmune Myocarditis. IL-17, IL-22 and their 
producing cells: role in inflammation and autoimmunity: Springer Basel. 2013:165–75.
[47]. Eriksson U, Kurrer MO, Sebald W, Brombacher F, Kopf M. Dual role of the IL-12/IFN-gamma 
axis in the development of autoimmune myocarditis: induction by IL-12 and protection by IFN-
gamma. J Immunol. 2001; 167:5464–9. [PubMed: 11673566] 
[48]. Baldeviano GC, Barin JG, Talor MV, Srinivasan S, Bedja D, Zheng D, et al. Interleukin-17A is 
dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res. 
2010; 106:1646–55. [PubMed: 20378858] 
[49]. Cosmi L, Maggi L, Santarlasci V, Liotta F, Annunziato F. T helper cells plasticity in 
inflammation. Cytometry Part A : the journal of the International Society for Analytical 
Cytology. 2014; 85:36–42. [PubMed: 24009159] 
[50]. Muranski P, Restifo NP. Essentials of Th17 cell commitment and plasticity. Blood. 2013; 
121:2402–14. [PubMed: 23325835] 
[51]. Ge S, Hertel B, Susnik N, Rong S, Dittrich AM, Schmitt R, et al. Interleukin 17 receptor A 
modulates monocyte subsets and macrophage generation in vivo. PLoS One. 2014; 9:e85461. 
[PubMed: 24454873] 
[52]. Kimizuka Y, Kimura S, Saga T, Ishii M, Hasegawa N, Betsuyaku T, et al. Roles of interleukin-17 
in an experimental Legionella pneumophila pneumonia model. Infect Immun. 2012; 80:1121–7. 
[PubMed: 22144493] 
[53]. Mosmann TR, Li L, Sad S. Functions of CD8 T-cell subsets secreting different cytokine patterns. 
Seminars in immunology. 1997; 9:87–92. [PubMed: 9194219] 
[54]. Yen HR, Harris TJ, Wada S, Grosso JF, Getnet D, Goldberg MV, et al. Tc17 CD8 T cells: 
functional plasticity and subset diversity. J Immunol. 2009; 183:7161–8. [PubMed: 19917680] 
[55]. Ford ML, Evavold BD. Specificity, magnitude, and kinetics of MOG-specific CD8+ T cell 
responses during experimental autoimmune encephalomyelitis. Eur J Immunol. 2005; 35:76–85. 
[PubMed: 15593305] 
[56]. Neumann F, Kubuschok B, Ertan K, Schormann C, Stevanovic S, Preuss KD, et al. A peptide 
epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4(+) 
and CD8(+) T-cell as well as B-cell responses. Cancer immunology, immunotherapy : CII. 2011; 
60:1333–46. [PubMed: 21630107] 
[57]. Sun D, Zhang Y, Wei B, Peiper SC, Shao H, Kaplan HJ. Encephalitogenic activity of truncated 
myelin oligodendrocyte glycoprotein (MOG) peptides and their recognition by CD8+ MOG-
specific T cells on oligomeric MHC class I molecules. Int Immunol. 2003; 15:261–8. [PubMed: 
12578856] 
[58]. Davila E, Kang YM, Park YW, Sawai H, He X, Pryshchep S, et al. Cell-based immunotherapy 
with suppressor CD8+ T cells in rheumatoid arthritis. J Immunol. 2005; 174:7292–301. 
[PubMed: 15905576] 
[59]. Dinesh RK, Skaggs BJ, La Cava A, Hahn BH, Singh RP. CD8+ Tregs in lupus, autoimmunity, 
and beyond. Autoimmun Rev. 2010; 9:560–8. [PubMed: 20385256] 
[60]. Strioga M, Pasukoniene V, Characiejus D. CD8+ CD28− and CD8+ CD57+ T cells and their role 
in health and disease. Immunology. 2011; 134:17–32. [PubMed: 21711350] 
[61]. Caforio AL, Goldman JH, Baig MK, Haven AJ, Dalla Libera L, Keeling PJ, et al. Cardiac 
autoantibodies in dilated cardiomyopathy become undetectable with disease progression. Heart. 
1997; 77:62–7. [PubMed: 9038697] 
[62]. Caforio AL, Goldman JH, Haven AJ, Baig KM, Libera LD, McKenna WJ. Circulating cardiac-
specific autoantibodies as markers of autoimmunity in clinical and biopsy-proven myocarditis. 
The Myocarditis Treatment Trial Investigators. Eur Heart J. 1997; 18:270–5. [PubMed: 9043844] 
Massilamany et al. Page 19
Int J Cardiol. Author manuscript; available in PMC 2017 January 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
[63]. Caforio AL, Mahon NJ, Tona F, McKenna WJ. Circulating cardiac autoantibodies in dilated 
cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail. 2002; 
4:411–7. [PubMed: 12167378] 
[64]. Kaya Z, Leib C, Katus HA. Autoantibodies in heart failure and cardiac dysfunction. Circ Res. 
2012; 110:145–58. [PubMed: 22223211] 
[65]. Neu N, Beisel KW, Traystman MD, Rose NR, Craig SW. Autoantibodies specific for the cardiac 
myosin isoform are found in mice susceptible to Coxsackievirus B3-induced myocarditis. J 
Immunol. 1987; 138:2488–92. [PubMed: 3031159] 
Massilamany et al. Page 20
Int J Cardiol. Author manuscript; available in PMC 2017 January 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Figure 1. FL-Myhc334-352 induces both CD4 and CD8 T cell responses
A/J mice were immunized with FL-Myhc334-352 in CFA; after 14 days animals were 
euthanized to prepare single cell suspensions from spleens and lymph nodes, from which 
CD4 and CD8 T cells were enriched by magnetic separation. The purity of CD4 and CD8 T 
cell preparations were ascertained by staining with antibodies for CD3, CD4 and CD8, and 
7-AAD, where the percentages of respective cell populations were determined within the 
live (7-AAD−) cells (top panel). Cells were stimulated with the irradiated APCs pulsed with 
the indicated peptides for two days. After pulsing with 3[H]-thymidine (1μCi/well) for 16 
hours, proliferative responses were measured as cpm. Mean ± SEM values derived from five 
experiments, each involving 5 to 8 mice are shown (bottom panels). RNase43-56 (control).
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Figure 2. The effector FL-Myhc334-352-sensitized CD8 T cells transfer disease to naïve recipients
(a) Histological evaluation of hearts. A/J mice were immunized with FL-Myhc334-352; 
after 14 days, CD8 T cells were enriched from spleens and lymph nodes. Cells were 
stimulated with Con-A for two days, and viable lymphoblasts were administered i.p. into 
naïve irradiated mice; each mouse also received pertussis toxin i.p. Whereas, naïve 
irradiated mice that received1 × PBS or Con-A stimulated CD8 T cells from unimmunized 
A/j mice served as controls. The animals were euthanized on day 18 post transfer, and hearts 
were examined by H and E staining. Panel-a (i and ii; Antigen-primed CD8 T cell-
recipients) shows lymphocyte infiltrations, hemorrhagic necrosis and mineralization; 
multifocal necrotic areas and degenerative leukocytes, respectively; panel-a (iii and iv) 
shows normal sections from recipients of saline or naïve CD8 T cells respectively. 
Representative sections are shown from experiments involving four to six mice per group. 
(b) Evaluation of the markers of effector CD8 T cells. LNC were isolated from mice 
immunized with Myhc334-352, and after stimulating with peptide for two days, cultures were 
maintained in IL-2 medium. CD8 T cells were tested for granzyme B and perforin 
intracellularly, and also for surface expression of CD107a/CD107b by flow cytometry using 
anti-mouse antibodies, and their frequencies were enumerated in the CD8 subset. Mean ± 
SEM values derived from seven experiments each involving three to six mice are shown.
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Figure 3. Evaluation of CD4 and CD8 T cell responses to the truncated peptides of FL-
Myhc334-352 (13 to 16-mers) in the primary screening
A/J mice were immunized with Myhc334-352 in CFA; after 14 days, single cell suspensions 
were prepared from spleens and lymph nodes, from which CD4 and CD8 T cells were 
enriched by magnetic separation. Cells were stimulated with Myhc334-352 and its truncated 
peptides (13 to 16-mers: Trunk A to D) in the presence of irradiated APCs for two days, 
followed by pulsing with 3[H]-thymidine. After 16 hours, proliferative responses were 
measured as cpm. RNase43-56 (control). Mean ± SEM values obtained from two individual 
experiments, each involving 10 to 11 mice are shown.
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Figure 4. Evaluation of CD4 and CD8 T cell responses to the short peptides of FL-Myhc334-352 
(10 to 11-mers) in the secondary screening
A/J mice were immunized with Myhc334-352 in CFA; after 14 days, CD4 and CD8 T cells 
were enriched by magnetic separation using the cell suspensions obtained from spleens and 
lymph nodes. Cells were stimulated with Myhc334-352 and short peptides (10 to 11-mers: 
Trunk A-4 to A-6) in the presence of irradiated APCs for two days, followed 16 hours later 
by pulsing with 3[H]-thymidine, the incorporation of which was measured as cpm. 
RNase43-56 (control). Mean ± SEM values obtained from two to four individual 
experiments, each involving 9 to 11 mice are shown.
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Figure 5. Determination of the binding of CD8 T cell epitopes to H-2Dd allele by MHC class I-
stabilization assay
RMA-S-Dd cells were incubated in the presence or absence of the indicated peptides (0 to 
400 μM) for 18 hours at 26°C; the plates were then transferred to a 37°C incubator and 
incubation continued for an additional 1.5 hours. After washing, cells were stained with 
fluorophore-conjugated H-2Dd antibody and acquired by flow cytometry. MFI values were 
obtained using CellQuest software. The MFI ratios were then derived using the formula as 
described in the section 2.6. Mean ± SEM values derived from five to six experiments are 
shown.
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Figure 6. Evaluation of antigen-specificity of CD8 T cells using MHC class I dextramers
LNC were obtained from animals immunized with Myhc334-352 and after cells were 
stimulated with the peptide for two days, IL-2 medium was supplemented. On day 8, cells 
were stained with the indicated H-2Dd dextramers, followed by anti-CD8, anti-CD4 and 7-
AAD. After washing, cells were acquired by flow cytometry, and the percentages of 
dextramer+ cells were analyzed in relation to CD4 and CD8 T cells by Flow Jo software. 
H-2Dd/Trunk A-6 and H-2Dd/HIVP18-I10 dextramers, control. Representative flow 
cytometric plots from one of the six experiments are shown (left panel). Mean ± SEM values 
derived from six experiments are shown (right panel).
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Figure 7. Cytokine responses to dual epitopes of FL-Myhc334-352 in CD4 and CD8 T cells
LNCs obtained from A/J mice immunized with Myhc334-352, Trunk A-4, Trunk A-5 or 
Trunk A-6 were stimulated with the immunizing peptides for two days, and the cultures 
were maintained in IL-2 medium. Cells were briefly stimulated on day 6 with PMA and 
ionomycin for 5 hours in the presence of monensin. After staining with anti-CD4, anti-CD8 
and 7-AAD, cells were fixed and permeabilized, and then stained with cytokine antibodies 
or their respective isotype controls. Cells were acquired by flow cytometry and the 
percentages of cytokine-producing cells in the live (7-AAD−) CD4 or CD8 T cell subsets 
were determined using Flow Jo software in relation to the gates drawn for isotype controls 
corresponding to each cytokine. Mean ± SEM values from four to six independent 
experiments are shown. In the left panel, cells positive for individual cytokines are shown 
(left, y-axis: IL-2, IFN-γ, IL-4, IL-10, IL-17A, IL-17F and IL-22; right, y-axis: TNF-α). The 
right panel shows the cytokine+ cells with respect to Th1 (IFN-γ), Th2 (IL-4 + IL-10) and 
Th17 (IL-17A + IL-17F + IL-22) subsets.
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Figure 8. Histological evaluation of hearts obtained from mice immunized with FL-Myhc334-352, 
and its truncated-derivatives, Trunk A-4 and Trunk A-5
Groups of A/J mice were immunized with Myhc334-352, Trunk A-4 or Trunk A-5 in CFA on 
day 0 and day 7, and the animals received pertussis toxin on day 0 and day 2 after the first 
immunization. Animals were euthanized 21 days later, and hearts were examined for 
inflammation by H and E staining. Arrows indicate lymphocytic infiltrations. Left panels 
(Myhc334-352-immunized group): epicardial infiltrates of lymphocytes and macrophages (i); 
subendocardial infiltrates of lymphocytes and macrophages extend into myocardium (ii); 
and interstitial myocardial infiltrates of macrophages and lymphocytes (iii). Middle panels 
(Trunk A-4-immunized group): subendocardial plasma cells, lymphocytes and macrophages 
extending into the myocardium (i); perivascular and interstitial lymphocytic and histiocytic 
infiltrates in the myocardium (ii); and subendocardial lymphocytes and macrophages (iii). 
Right panels (Trunk A-5-immunized group): interstitial lymphocytes and macrophages in 
myocardium (i); subendocardial lymphocytes and a few macrophages and rare plasma cells 
infiltrate the atria (ii); and small foci of lymphocytes in subendocardium (iii).
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Table 1
The list of peptides used to evaluate CD4 and CD8 T cell responses in the primary screening
Peptide Sequence
minor major
TCR contacts 344 348
↑ ↑
FL-Myhc334-352 DSAFDVLSFTAEEKAGVYK†
↓
338 MHC-anchor
Trunk A (Myhc334-349) DSAFDVLSFTAEEKAG
Trunk B (Myhc338-352) DVLSFTAEEKAGVYK
Trunk C (Myhc334-347) DSAFDVLSFTAEEK
Trunk D (Myhc340-352) LSFTAEEKAGVYK
†
putative MHC class II (IAk)-binding residue is shown with dotted arrow and two TCR-contact residues are shown with bold arrows
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Table 2
The list of peptides used to evaluate CD4 and CD8 T cell responses in the secondary screening
Peptide Sequence
Trunk A (Myhc334-349) DSAFDVLSFTAEEKAG
Trunk A-1 (Myhc340-349) LSFTAEEKAG
Trunk A-2 (Myhc339-349) VLSFTAEEKAG
Trunk A-3 (Myhc338-349) DVLSFTAEEKAG
Trunk A-4 (Myhc338-348) DVLSFTAEEKA
Trunk A-5 (Myhc338-347) DVLSFTAEEK
Trunk A-6 (Myhc339-348) VLSFTAEEKA
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